Research output per year
Research output per year
Fingerprint
Dive into the research topics where Karen Buttigieg is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2
Huang, K. Y. A., Zhou, D., Tan, T. K., Chen, C., Duyvesteyn, H. M. E., Zhao, Y., Ginn, H. M., Qin, L., Rijal, P., Schimanski, L., Donat, R., Harding, A., Gilbert-Jaramillo, J., James, W., Tree, J. A., Buttigieg, K., Carroll, M., Charlton, S., Lien, C. E., Lin, M. Y. & 9 others, , 1 Jan 2022, In: Theranostics. 12, 1, p. 1-17 17 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile -
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
Tan, T. K., Rijal, P., Rahikainen, R., Keeble, A. H., Schimanski, L., Hussain, S., Harvey, R., Hayes, J. W. P., Edwards, J. C., McLean, R. K., Martini, V., Pedrera, M., Thakur, N., Conceicao, C., Dietrich, I., Shelton, H., Ludi, A., Wilsden, G., Browning, C., Zagrajek, A. K. & 34 others, , 22 Jan 2021, In: Nature Communications. 12, 1, 16 p., 542.Research output: Contribution to journal › Article › peer-review
Open Access41 Citations (Scopus) -
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
Huo, J., Mikolajek, H., Le Bas, A., Clark, J. J., Sharma, P., Kipar, A., Dormon, J., Norman, C., Weckener, M., Clare, D. K., Harrison, P. J., Tree, J. A., Buttigieg, K. R., Salguero, F. J., Watson, R., Knott, D., Carnell, O., Ngabo, D., Elmore, M. J., Fotheringham, S. & 13 others, , Dec 2021, In: Nature Communications. 12, 1, 5469.Research output: Contribution to journal › Article › peer-review
Open AccessFile6 Citations (Scopus)3 Downloads (Pure) -
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (Nature Medicine, (2021), 27, 2, (270-278), 10.1038/s41591-020-01194-5)
the Oxford COVID Vaccine Trial Group, Jun 2021, In: Nature Medicine. 27, 6, p. 1116 1 p.Research output: Contribution to journal › Comment/debate
Open Access1 Citation (Scopus) -
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (Nature Medicine, (2021), 27, 2, (279-288), 10.1038/s41591-020-01179-4)
the Oxford COVID Vaccine Trial Group, Jun 2021, In: Nature Medicine. 27, 6, p. 1113 1 p.Research output: Contribution to journal › Comment/debate
Open Access2 Citations (Scopus)